New obesity drug shows promise in major japanese trial
NCT ID NCT06987695
First seen Nov 06, 2025 · Last updated May 09, 2026 · Updated 22 times
Summary
This study tests a new medication called maridebart cafraglutide for weight loss in 279 Japanese adults with obesity. Participants receive either the drug or a placebo for 72 weeks. The main goals are to see how much weight they lose and if at least 5% of body weight is lost. This is a phase 3 trial, meaning it is in the final stage before possible approval.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Adachi Kyosai Hospital
Adachi-ku, Tokyo, 120-0022, Japan
-
Aira Diabetes Thyroid Internal Medicine Clinic
Aira-shi, Kagoshima-ken, 899-5421, Japan
-
Deguchi Clinic
Kobe, Hyōgo, 652-0803, Japan
-
Fukuoka Shinmizumaki Hospital
Onga-gun, Fukuoka, 807-0051, Japan
-
Hosokawa Surgical Clinic
Nagoya, Aichi-ken, 453-0812, Japan
-
Ikebukuro Metropolitan Clinic
Toshima-ku, Tokyo, 171-0021, Japan
-
Joh Medical Clinic
Osaka, Osaka, 530-0002, Japan
-
Kobe University Hospital
Kobe, Hyōgo, 650-0017, Japan
-
Kyoto University Hospital
Kyoto, Kyoto, 606-8507, Japan
-
Kyushu University Hospital
Fukuoka, Fukuoka, 812-8582, Japan
-
MIH Clinic Yoyogi
Shibuya-ku, Tokyo, 151-0051, Japan
-
Manda Memorial Hospital
Sapporo, Hokkaido, 060-0062, Japan
-
Matsuba Clinic
Kawasaki-shi, Kanagawa, 212-0024, Japan
-
Matsunami Health Promotion Clinic
Hashima-gun, Gifu, 501-6061, Japan
-
Medical Corporation Boocs Boocs Clinic Fukuoka
Fukuoka, Fukuoka, 812-0025, Japan
-
Medical Corporation Chiseikai Tokyo Center Clinic
Chuo-ku, Tokyo, 103-0027, Japan
-
Medical Corporation Keiseikai Kajiyama Clinic
Kyoto, Kyoto, 600-8898, Japan
-
Medical Corporation Kenshinkai Minamino Cardiovascular Hospital
Hachioji-shi, Tokyo, 192-0918, Japan
-
Meitetsu Hospital
Nagoya, Aichi-ken, 451-8511, Japan
-
Midori Clinic
Nagasaki, Nagasaki, 852-8034, Japan
-
Nihonbashi Sakura Clinic
Chuo-ku, Tokyo, 103-0025, Japan
-
Nishiyamado Keiwa Hospital
Naka, Ibaraki, 311-0133, Japan
-
Shimamura Memorial Hospital
Nerima-ku, Tokyo, 177-0051, Japan
-
Shinjuku Southern Clinic
Shinjuku-ku, Tokyo, 160-0023, Japan
-
Social Medical Corporation Kojunkai Daido Clinic
Nagoya, Aichi-ken, 457-8511, Japan
-
Tashiro Endocrinology Clinic
Fukuoka, Fukuoka, 814-0153, Japan
-
Tokyo Saiseikai Central Hospital
Minato-ku, Tokyo, 108-0073, Japan
-
Urasoe General Hospital
Urasoe-shi, Okinawa, 901-2102, Japan
-
Wellness Tenjin Clinic
Fukuoka, Fukuoka, 810-0001, Japan
-
Yamasaki Family Clinic
Amagasaki-shi, Hyōgo, 660-0861, Japan
Conditions
Explore the condition pages connected to this study.